INC424

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Myelofibrosis

Conditions

Myelofibrosis

Trial Timeline

Aug 16, 2011 → Jan 26, 2017

NCT ID

NCT01493414

About INC424

INC424 is a phase 3 stage product being developed by Novartis for Myelofibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01493414. Target conditions include Myelofibrosis.

What happened to similar drugs?

2 of 18 similar drugs in Myelofibrosis were approved

Approved (2) Terminated (3) Active (13)

🔄Placebo for Navitoclax + Ruxolitinib + NavitoclaxAbbViePhase 3

🔄Navitoclax + Ruxolitinib + Best Available Therapy (BAT)AbbViePhase 3

❌Ruxolitinib + Ruxolitinib PlaceboNovartisPhase 3

🔄Pelabresib + Ruxolitinib + PlaceboNovartisPhase 3

✅ruxolitinib + panobinostatNovartisApproved

🔄Pelabresib + Ruxolitinib + PlaceboNovartisPhase 3

✅INC424NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03774082	Phase 2	Completed	May 20, 2020	Aug 26, 2024	Graft vs Host Disease
NCT01558739	Approved	Completed	May 1, 2012	Jan 1, 2014	Primary Myelofibrosis (PMF)
NCT01493414	Phase 3	Completed	Aug 16, 2011	Jan 26, 2017	Myelofibrosis

Competing Products

20 competing products in Myelofibrosis

See all competitors

Product	Company	Stage	Hype Score
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Nusivertib + Ruxolitinib + Momelotinib	Sumitomo Pharma	Phase 1/2	39
Ruxolitinib + Navitoclax	AbbVie	Phase 2	35
ABBV-744 + Navitoclax + Ruxolitinib	AbbVie	Phase 1	33
Placebo for Navitoclax + Ruxolitinib + Navitoclax	AbbVie	Phase 3	40
Mivebresib + Navitoclax + Ruxolitinib	AbbVie	Phase 1	21
Navitoclax + Venetoclax	AbbVie	Pre-clinical	26
Navitoclax + Ruxolitinib + Best Available Therapy (BAT)	AbbVie	Phase 3	44
NS-018 + Best Available Therapy	Nippon Shinyaku	Phase 2	27
AZD1480	AstraZeneca	Phase 1	29
Bomedemstat	Merck	Phase 2	31
Peginterferon alfa-2a	Merck	Phase 2	27
Bomedemstat	Merck	Phase 1/2	32
MBG453 + NIS793 + Spartalizumab + Decitabine	Novartis	Phase 1	21
PIM447 + Ruxolitinib + LEE011	Novartis	Phase 1	29
LDE225 + INC424	Novartis	Phase 1/2	32
Imatinib mesylate	Novartis	Phase 2	35
Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793	Novartis	Phase 1/2	24
Ruxolitinib + Ruxolitinib Placebo	Novartis	Phase 3	32
Ruxolitinib	Novartis	Pre-clinical	30